Affiliation:
1. Medical Oncology and Hematology, Princess Margaret Cancer Centre University of Toronto Toronto Ontario Canada
Abstract
Evidence‐based guidelines for rare diseases, such as myelofibrosis (MF), continue to prove challenging to develop, and decision‐making for MF is complex. The British Society for Haematology (BSH) has created a pragmatic symptom‐guided risk‐adapted framework on all aspects of management of MF and shared best practices on the use of JAK inhibitors, transplantation and other conventional therapies in the management of myelofibrosis.Commentary on: McLornan et al. The management of myelofibrosis: A British Society for Haematology Guideline. Br J Haematol 2024;204:136–150.